Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era
SM McCluskey, T Pepperrell, A Hill, WDF Venter… - Aids, 2021 - journals.lww.com
Dolutegravir (DTG) is now a component of preferred first-line antiretroviral therapy (ART)
worldwide. ADVANCE and NAMSAL were two landmark clinical trials conducted exclusively …
worldwide. ADVANCE and NAMSAL were two landmark clinical trials conducted exclusively …
Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: A …
A Abdullahi, IM Kida, UA Maina… - Journal of …, 2023 - academic.oup.com
Background Due to the high prevalence of resistance to NNRTI-based ART since 2018,
consolidated recommendations from the WHO have indicated dolutegravir as the preferred …
consolidated recommendations from the WHO have indicated dolutegravir as the preferred …
New antiretroviral inhibitors and HIV-1 drug resistance: more focus on 90% HIV-1 isolates?
E Ndashimye, PS Reyes, EJ Arts - FEMS Microbiology Reviews, 2023 - academic.oup.com
Combined HIV antiretroviral therapy (cART) has been effective except if drug resistance
emerges. As cART has been rolled out in low-income countries, drug resistance has …
emerges. As cART has been rolled out in low-income countries, drug resistance has …
Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance
PL Tzou, SY Rhee, D Descamps… - Journal of …, 2020 - academic.oup.com
Background Integrase strand transfer inhibitors (INSTIs) are expected to be widely adopted
globally, requiring surveillance of resistance emergence and transmission. Objectives We …
globally, requiring surveillance of resistance emergence and transmission. Objectives We …
The urgent need for more potent antiretroviral therapy in low-income countries to achieve UNAIDS 90-90-90 and complete eradication of AIDS by 2030
E Ndashimye, EJ Arts - Infectious Diseases of Poverty, 2019 - mednexus.org
Background: Over 90% of Human Immunodeficiency Virus (HIV) infected individuals will be
on treatment by 2020under UNAIDS 90-90-90 global targets. Under World Health …
on treatment by 2020under UNAIDS 90-90-90 global targets. Under World Health …
Pre-treatment HIV-1 drug resistance in antiretroviral therapy-naive adults in Eastern Africa: a systematic review and meta-analysis
AJ Ntamatungiro, J Kagura, M Weisser… - Journal of …, 2022 - academic.oup.com
Background Pre-treatment HIV drug resistance (PDR) may result in increased risk of
virological failure and acquisition of new resistance mutations. With recently increasing ART …
virological failure and acquisition of new resistance mutations. With recently increasing ART …
Transitioning to dolutegravir in a programmatic setting: Virological outcomes and associated factors among treatment-naïve patients with HIV-1 in the Kilombero and …
AJ Ntamatungiro, A Eichenberger… - Open forum …, 2023 - academic.oup.com
Background Virological outcome data after programmatic transition from non-nucleoside
reverse transcriptase inhibitor (NNRTI)-based to dolutegravir (DTG)-based antiretroviral …
reverse transcriptase inhibitor (NNRTI)-based to dolutegravir (DTG)-based antiretroviral …
Pre-treatment integrase inhibitor resistance and natural polymorphisms among HIV-1 subtype C infected patients in Ethiopia
DA Arimide, ZI Szojka, K Zealiyas, A Gebreegziabxier… - Viruses, 2022 - mdpi.com
Dolutegravir-based antiretroviral therapy (ART) has been scaled up in many developing
countries, including Ethiopia. However, subtype-dependent polymorphic differences might …
countries, including Ethiopia. However, subtype-dependent polymorphic differences might …
High-level resistance to bictegravir and cabotegravir in subtype A-and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations
E Ndashimye, Y Li, PS Reyes, M Avino… - Journal of …, 2021 - academic.oup.com
Objectives The second-generation integrase strand transfer inhibitor (INSTI) bictegravir is
becoming accessible in low-and middle-income countries (LMICs), and another INSTI …
becoming accessible in low-and middle-income countries (LMICs), and another INSTI …
Primary resistance against integrase strand transfer inhibitors in integrase strand transfer inhibitor-naive patients failing first-and second-line ART in Tanzania
S Henerico, E Lyimo, AN Makubi… - Journal of …, 2022 - academic.oup.com
Abstract Introduction Sub-Saharan African countries are introducing integrase strand
transfer inhibitors (INSTIs) in their ART programmes as the preferred first-line regimen, and …
transfer inhibitors (INSTIs) in their ART programmes as the preferred first-line regimen, and …